-
West Midlands Shoppers Urged to Guard Against Black Friday Scams
-
GIRLBAND! Headline Show at Rough Trade Marks National Breakthrough
-
Surfshark Adds Real-Time Call Protection to iOS App in Version 5.3.0
-
Samsung Galaxy Buds Active Leak Reveals ANC, Ear-Hook Design and One UI 9.5 Integration
-
Saudi PIF Retains Top Sovereign Wealth Fund Brand Title for Third Year
-
Egypt and Syria Sign Agreement to Restore Direct Flights After 14-Year Hiatus
-
Professor Shahida Moosa Pioneers Medical Genomics in South Africa Amid Testing Shortages
-
Van Gogh’s ‘Châtaigniers en Fleurs’ Sets $285m Record at Sotheby’s
-
Texas Marijuana Decriminalization Faces Uncertain Future Under New Attorney General
-
Anthropic Sets Record $81.3 Billion IPO Valuing AI Firm at $1.5 Trillion
-
Early Black Friday Laptop Deals: MacBook Neo, IdeaPad Slim 5x, and Surface Laptop Prices Drop
-
eThekwini Faces R6.5bn Flood Claim from Toyota’s Insurer
-
2026 East Bay Nosh Awards Voting Opens for Food and Drink Favorites
-
More Than Half of Teen AI Chatbot Users Use Them Daily, and 46% Say It Feels Like Talking to a Human, New Family Online Safety Institute Research Finds
-
After 20 Years of Modernizing Other Companies' Software, Polcode Turns the Lens on Itself
-
MicroVision and Blue-Band to Support $3 Million Federally Funded Intelligent Transportation Initiative in Louisville, Kentucky
-
The 2026 MDaudit Annual Benchmark Report Spotlights AI's Impact on Financial Risk as Payer Denials and Audits Continue an Upward Trajectory
-
Metano Emerges From Stealth to Unify AI Agent Security Across the Enterprise
-
Lumber's Union CBA Agent Launches in Sage Agent Marketplace to Help Simplify Union Payroll Compliance
-
ATWEC Technologies, Inc. (OTCID: ATWT) Engages Michael Gillespie & Associates, PLLC to Audit Fiscal 2026 and 2025 Consolidated Financial Statements and Changes Fiscal Year End to October 31
-
Vogenx Set to Join the Russell 2000(R), Russell 3000(R), and Russell Microcap(R) Indexes
-
Stemtech Corporation Partners with Fitness Icon Tony Little to Launch Stemtech Biosciences Digital Campaign
-
Go Green Global Technologies Corp. Appoints Dennis Beckert as Interim Chief Executive Officer
-
InstaLILY Launches Lily for Sales on Microsoft Dynamics 365, Where Sellers and AI Agents Work Together in Shared Rooms
-
Wave AI, the AI Note Taker for In-Person Meetings, Passes 5 Million Recorded Hours
-
Increasing Electrification Raises Grid Risk and Cost Pressure for Industrial Sites, ABI Research Finds
-
Jerash Holdings Partners with International Finance Corporation (IFC) to Pursue EDGE Gender Certification
-
Lexaria's Human Study GLP-1-H26-7 Completes Dosing as Scheduled
-
Philadelphia Sexual Assault Lawyer David P. Thiruselvam Explains Who Can Be Named in a Civil Sexual Assault Claim
-
Long Island Capital Alliance to Host Technology Capital Forum
-
BlackBerry and Hazard Management Cayman Islands Renew Critical Alerting System for Emergencies and Public Safety
-
Celtic Bank Selects Infinant to Scale Its Embedded Finance Programs
-
Making the Most of a Long Weekend Without Leaving Town
-
Gamma Resources Announces Expansion of Mesa Arc Uranium Project in New Mexico to 4,760 Acres, Completes Radon Flux Baseline Survey
-
Bob's Watches Founder Paul Altieri Unveils Private Collection of Vintage Rolex Watches in New Book, "NOT FOR SALE"
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 19
-
Hemogenyx Pharmaceuticals PLC - Chairman Receives Prestigious Award
-
American Critical Minerals Reports High Grade Potash Intersection of 6.55m Grading 38.51 wt.% KCl at its Green River Project, Utah
-
LASE to Premiere Quantum Bullet(TM) at Counter UAS Technology Conference in Washington, D.C.
-
First Canadian Graphite Reports 43.9% Graphitic Carbon Sample and Encouraging Coarse-Flake Characteristics at Zone 13 at Lac Guéret South
-
IRS Shuts Down FIRE Today: What Information Return Filers Need to Know Before the 2027 Filing Season
-
NoHo, Inc. Acquires Four Placer Gold Claims in Clark County, Nevada from Gold Stake Mining Inc.
-
Trustpoint Xposure Completes More Than 200 AI Visibility Audits Across Professional Services
-
QNX Brings Physical AI and Next-Generation Software-Defined Vehicle Innovation to CES 2027
-
Golden Minerals Completes Drilling Desierto, Argentina
-
Guanajuato Silver Reports Q3 Operating and Financial Results
-
Helio Corporation Engages CORE IR to Provide Investor Relations, Capital Markets Advisory and Media Relations Services
-
Greene Concepts Connects Consumer Needs with Manufacturing Strategy
-
Karbon-X (OTCQB:KARX) Enters California's Multi-Billion-Dollar Compliance Carbon Market Following CITSS Approval
-
Skilled Nursing Facilities Face 2027 Revenue Cycle Reckoning as Payer Burdens Reshape Admissions and Outsourcing
New hope for patients with less common breast cancer
A new treatment nearly halves the risk of disease progression or death from a less common form of breast cancer that hasn't seen major drug advances in over a decade, researchers reported Monday.
Results from the study, presented at the annual meeting of the American Society for Clinical Oncology, are expected to be submitted to regulators and could soon establish a new first-line therapy for people with HER2-positive metastatic breast cancer -- the advanced stage of a form that comprises 15–20 percent of all breast cancer cases.
HER2-positive cancers are fueled by an overactive HER2 gene, which makes too much of a protein called human epidermal growth factor receptor 2 that helps cancer cells grow and spread.
Patients with HER2-positive breast cancer that has spread to other parts of the body live around five years.
"Seeing such a striking improvement was really impressive to us -- we were taking a standard and almost doubling how long patients could have their cancer controlled for," oncologist Sara Tolaney, chief of the breast oncology division at Dana-Farber Cancer Institute, told AFP.
The current standard of care, known as THP, combines chemotherapy with two antibodies that block growth signals from the HER2 protein. The new approach uses a drug called trastuzumab deruxtecan (T-DXd), an antibody attached to a chemotherapy drug.
- 'Smart bomb' -
This "smart bomb" strategy allows the drug to target cancer cells directly. "You can bind to the cancer cell and dump all that chemo right into the cancer cells," explained Tolaney.
"Some people call them smart bombs because they're delivering chemo in a targeted fashion -- which is how I think we're able to really increase efficacy so much."
Common side effects included nausea, diarrhea and a low white blood cell count, with a less common effect involving lung scarring.
T-DXd is already approved as a "second-line" option -- used when first-line treatments stop working. But in the new trial, it was given earlier, paired with another antibody, pertuzumab.
In a global trial led by Tolaney, just under 400 patients were randomly assigned to receive T-DXd in combination with pertuzumab, thought to enhance its effects.
A similar number received the standard THP regimen. A third group, who received T-DXd without pertuzumab, was also enrolled -- but those results haven't yet been reported.
- 44 percent risk reduction -
At a follow-up of 2.5 years, the T-DXd and pertuzumab combination reduced the risk of disease progression or death by 44 percent compared to standard care.
Fifteen percent of patients in the T-DXd group saw their cancer disappear entirely, compared to 8.5 percent in the THP group.
Because this was an interim analysis, the median progression-free survival -- meaning the point at which half the patients had seen their cancer return or worsen -- was 40.7 months with the new treatment, compared to 26.9 months with the standard, and could rise further as more data come in.
Tolaney said the results would be submitted to regulators around the world, including the US Food and Drug Administration, and that future work would focus on optimizing how long patients remain on the treatment, particularly those showing complete remission.
"This represents a new first-line standard treatment option for HER2-positive metastatic breast cancer," said Dr. Rebecca Dent, a breast cancer specialist at the National Cancer Center Singapore who was not involved in the study
Ch.Kahalev--AMWN